What does this video actually claim?
Corrine Benandi shows her progress after 5 weeks on tirzepatide, tagging Clay Health as her provider. The video itself makes minimal specific claims, focusing on visual before/after content rather than detailed medical statements.
She's documenting her journey on what appears to be Mounjaro or Zepbound (tirzepatide), a GLP-1/GIP dual agonist that's FDA-approved for diabetes and obesity. Her enthusiasm suggests she's seeing results, though the video doesn't quantify weight loss or discuss dosing details.
The real question isn't what she claims, but whether her timeline matches what clinical data shows we should expect from tirzepatide at the 5-week mark.
Does 5 weeks align with clinical trial timelines?
Yes, but barely. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed early weight loss starting around week 4-6 on tirzepatide. Most patients don't hit peak doses until week 16-20 due to required titration schedules.
At 5 weeks, patients typically take 2.5mg weekly (the second dose level) after starting at 2.5mg for 4 weeks. Real weight loss acceleration usually happens between weeks 8-16 when doses reach 7.5mg to 15mg weekly.
Her timing isn't unrealistic, but it's early days. The SURMOUNT-1 trial's most impressive results (20.9% weight loss at 72 weeks with 15mg doses) took months to materialize, not weeks.
What does Clay Health actually offer?
Clay Health operates as a telehealth platform prescribing GLP-1 medications including tirzepatide. They're one of dozens of similar services that emerged after semaglutide and tirzepatide gained popularity for weight management.
These platforms typically charge $199-399 monthly for medication access plus consultation fees. They can legally prescribe FDA-approved medications, but patients should understand they're paying premium prices compared to traditional healthcare routes with insurance coverage.
The company appears legitimate, but like most telehealth weight loss services, they're selling convenience and accessibility rather than specialized medical expertise you can't get elsewhere.
What should you know about tirzepatide at 5 weeks?
Real results take patience. The SURMOUNT trials showed average weight loss of 15% (5mg), 19.5% (10mg), and 20.9% (15mg) at 72 weeks. That's not 5 weeks.
Most patients experience nausea, diarrhea, and decreased appetite during the first 4-8 weeks as common side effects. The medication works by slowing gastric emptying and affecting brain appetite centers, but these effects strengthen as doses increase over months.
Individual results vary significantly. Some patients see minimal results at lower doses, while others respond well early on. Corrine's enthusiasm at week 5 could reflect real progress or normal medication honeymoon period optimism.